Stock Titan

Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

Divarasib also reduced progression-or-death risk by 42%; no new safety signals were observed. Results appeared in The New ...